Suppr超能文献

比较肥胖患者与非肥胖患者的华法林初始反应。

Comparison of initial warfarin response in obese patients versus non-obese patients.

机构信息

Department of Clinical Pharmacy, University of Tennessee Health Science Center UTHSC, 881 Madison Ave., Room 235, Memphis, TN 38163, USA.

出版信息

J Thromb Thrombolysis. 2013 Jul;36(1):96-101. doi: 10.1007/s11239-012-0811-x.

Abstract

Achieving therapeutic anticoagulation with warfarin is complicated by substantial inter-patient and intra-patient variability with numerous factors known to influence dose requirements. Obesity is one factor for which there remains no study to date investigating its initial effect on warfarin response assessed by INR, stratified by BMI category in hospitalized patients. To compare initial warfarin response between obese and non-obese patients by evaluating average daily dose (ADD), time required to attain therapeutic INR, and mean discharge dose (MDD), stratified by BMI category. A retrospective review was conducted to evaluate initial warfarin response in hospitalized patients of different BMI categories initiated on warfarin with ≥4 consecutive days of therapy and managed by pharmacy dosing service. 211 patients were included (10 underweight, 45 normal weight, 48 overweight, 71 obese, 37 morbidly obese). Across BMI categories, the percentage of patients attaining therapeutic INR prior to discharge differed (p = 0.0004) with 71.1 % of normal weight therapeutic compared to 42.3 % of obese and 38 % of morbidly obese. Within BMI categories, when comparing ADD between patients therapeutic and subtherapeutic at discharge, no differences were observed, except among overweight patients (5.6 ± 0.3 vs. 7 ± 0.4 mg, p = 0.0143). Compared to normal weight, obese and morbidly obese required a significantly longer median time to achieve therapeutic INR (8 and 10 days vs. 6 days) and a higher ADD (6.6 ± 0.3 and 7.6 ± 0.5 vs. 5 ± 0.3 mg) and MDD (6.7 ± 0.5 and 6.7 ± 0.7 vs. 4.4 ± 0.5 mg). Compared to normal weight, obese and morbidly obese patients had a decreased initial response to warfarin.

摘要

华法林治疗的抗凝效果受患者间和患者内的显著差异影响,许多因素已知会影响剂量需求。肥胖是一个尚未有研究调查其对住院患者 INR 评估的初始影响的因素,且未按 BMI 类别分层。本研究旨在比较肥胖和非肥胖患者的初始华法林反应,通过评估平均日剂量(ADD)、达到治疗性 INR 所需的时间和平均出院剂量(MDD),并按 BMI 类别分层。对接受华法林治疗且至少连续 4 天治疗的不同 BMI 类别住院患者进行回顾性评估,这些患者由药房剂量服务管理。共纳入 211 例患者(10 例体重不足、45 例体重正常、48 例超重、71 例肥胖、37 例病态肥胖)。在不同 BMI 类别中,达到出院时治疗性 INR 的患者比例不同(p=0.0004),体重正常者的比例为 71.1%,而肥胖者和病态肥胖者的比例分别为 42.3%和 38%。在 BMI 类别内,当比较出院时治疗性和亚治疗性患者的 ADD 时,除超重患者外(5.6±0.3 与 7±0.4 mg,p=0.0143),未观察到差异。与体重正常者相比,肥胖和病态肥胖者达到治疗性 INR 的中位时间显著延长(8 天和 10 天与 6 天),ADD 更高(6.6±0.3 和 7.6±0.5 与 5±0.3 mg),MDD 更高(6.7±0.5 和 6.7±0.7 与 4.4±0.5 mg)。与体重正常者相比,肥胖和病态肥胖患者对华法林的初始反应降低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验